首页 › 非小细胞肺癌 › 肯塔基州 › Lexington
Lexington KY 非小细胞肺癌临床试验
23项针对 非小细胞肺癌的研究正在 Lexington及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- Baptist Health Lexington, Lexington
- Baptist Health Hamburg, Lexington
- University of Kentucky/Markey Cancer Center, Lexington
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- Local Institution - 0034, Lexington
- Local Institution - 0171, Lexington
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
招募中2 期
- University of Kentucky Chandler Medical Center ( Site 0019), Lexington
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
招募中3 期
- University of Kentucky Chandler Medical Center, Lexington
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
招募中3 期
- Research Site, Lexington
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
招募中3 期
- Baptist Health Lexington, Lexington
- Baptist Health Hamburg, Lexington
Pan-tumor MRD Study
招募中观察性研究
- Baptist Health Lexington, Lexington
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
招募中3 期
- Baptist Health Lexington, Lexington
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
招募中2/3 期
- Baptist Health Lexington, Lexington
- University of Kentucky Chandler Medical Center (UKCMC) - Markey Cancer Center (Lucille P. Markey Cancer Center), Lexington
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
招募中3 期
- Research Site, Lexington
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
招募中3 期
- Clinical Study Site, Lexington
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
招募中2/3 期
- Lexington Medical Cancer Center Hematology/Oncology, Lexington
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
招募中1/2 期
- Markey Cancer Center, Lexington
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
招募中2/3 期
- Baptist Health Lexington /ID# 261823, Lexington
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
招募中3 期
- CHI Saint Joseph Cancer Center - East, Lexington
- University of Kentucky Chandler Medical Center, Lexington
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
招募中2 期
- University of Kentucky ( Site 0019), Lexington
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
招募中1 期
- University of Kentucky Chandler Medical Center, Lexington
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
招募中1 期
- UK Markey Cancer Center, Lexington
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
招募中2 期
- University of Kentucky/Markey Cancer Center, Lexington
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- University of Kentucky/Markey Cancer Center, Lexington
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
招募中2/3 期
- University of Kentucky/Markey Cancer Center, Lexington
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- University of Kentucky/Markey Cancer Center, Lexington
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
招募中观察性研究
- Saint Joseph Hospital East, Lexington
其他城市的 非小细胞肺癌试验
- Houston, TX145 项研究
- New York City, NY121 项研究
- Arlington, VA104 项研究
- Nashville, TN97 项研究
- Boston, MA90 项研究
- Los Angeles, CA87 项研究
- St. Louis, MO73 项研究
- Chicago, IL61 项研究
- Baltimore, MD60 项研究
- San Antonio, TX59 项研究
- Columbus, OH57 项研究
- Washington, DC55 项研究
Lexington的其他研究
- 肺癌18 项研究
- 卵巢癌16 项研究
- 前列腺癌14 项研究
- 癌症（所有类型）14 项研究
- 乳腺癌14 项研究
- 转移性癌症11 项研究
- 结直肠癌11 项研究
- 心力衰竭11 项研究
- 黑色素瘤10 项研究
- 急性髓系白血病10 项研究
- 肥胖症10 项研究
- 头颈鳞状细胞癌9 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。